Bone loss and depot medroxyprogesterone [2] (multiple letters)

American Journal of Obstetrics and Gynecology

Volumn 176, Issue 5, 1997, Pages 1116-1117

  Cundy, T ^a   Reid, I R ^a   Vercellini, P ^a   Crosignani, P G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

BONE ATROPHY; DRUG SAFETY; ENDOMETRIOSIS; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LETTER; ORAL DRUG ADMINISTRATION; PELVIS PAIN SYNDROME; PRIORITY JOURNAL;

EID: 0030978348     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)70415-0     Document Type: Letter

References (3)

1. T Cundy MC Evans H Roberts D Wattie R Ames IR Reid Bone density in women receiving depot medroxyprogesterone acetate for contraception BMJ 303 1991 13 16 [published erratum appears in BMJ 1991; 303: 202]
2. T Cundy J Cornish MC Evans H Roberts IR Reid Recovery of bone density in women who stop using depot medroxyprogesterone acetate BMJ 308 1993 247 248
3. T Cundy CM Farquhar J Cornish IR Reid Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women J Clin Endocrinol Metab 81 1996 1010 1017